Treatment of Men with Erectile Dysfunction with Transurethral Alprostadil
Open accessAbstract
Background Erectile dysfunction in men is common. We evaluated a system by which alprostadil (prostaglandin E1) is delivered transurethrally to treat this disorder. Methods Alprostadil was delivered transurethrally in a double-blind, placebo-controlled study of 1511 men, 27 to 88 years of age, who had chronic erectile dysfunction from various organic causes. The men were first tested in the clinic with up to four doses of the drug (125, 250, 500, and 1000 microg); those who had sufficient responses were randomly assigned to treatment with either the effective dose of alprostadil or placebo for three months at home. Results During in-clinic testing, 996 men (65.9 percent) had erections sufficient for intercourse. Of these men, 961 reported the results of at least one home treatment; 299 of the 461 treated with alprostadil (64.9 percent) had intercourse successfully at least once, as compared with 93 of the 500 who received placebo (18.6 percent, P Conclusions In men with erectile dysfunction, transurethral alprostadil therapy resulted in erections in the clinic and in intercourse at home.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Transurethral alprostadil at a higher dose (250-1000 μg) is a therapy for erectile dysfunction with a success rate of 40-69%.
“Alprostadil used in intracavernous injection can be applied transurethrally at a higher dose (250-1000 µg) as a therapy for ED with a success rate of 40-69% [32-35].”
From Erectile dysfunction and its pharmacology: An overview (2017) · cites this paper as [33]
Adverse events associated with transurethral alprostadil include urethral pain and injury, vasovagal reflex, hypotension, and priapism (<0.1%).
“Adverse events associated with transurethral alprostadil include urethral pain and injury, vasovagal reflex, hypotension, and priapism (<0.1%).”
From Erectile dysfunction and its pharmacology: An overview (2017) · cites this paper as [33]
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646 · see citing works
Rajfer, J., Aronson, W. J., Bush, P. A., Dorey, F. J., & Ignarro, L. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260203 · Cited by 1,006 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1553 · Cited by 2,044 · see citing works
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation
Hatzimouratidis, K., Amar, E., Eardley, I., Giuliano, F., Hatzichristou, D., Montorsi, F., Vardi, Y., & Wespes, E. (2010) · European Urology · doi:10.1016/j.eururo.2010.02.020 · Cited by 1,223 · see citing works
Erectile dysfunction: AUA guideline
Burnett, A. L., Nehra, A., Breau, R. H., Culkin, D. J., Faraday, M. M., Hakim, L. S., Heidelbaugh, J., Khera, M., McVary, K. T., Miner, M. M., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2018.05.004 · Cited by 949 · see citing works
Yafi, F. A., Jenkins, L., Albersen, M., Corona, G., Isidori, A. M., Goldfarb, S., Maggi, M., Nelson, C. J., Parish, S., Salonia, A., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.3 · Cited by 853 · see citing works
Jannini, E. A., Screponi, E., Carosa, E., Pepe, M., Lo Giudice, F., Trimarchi, F., & Benvenga, S. (1999) · International Journal of Andrology · doi:10.1046/j.1365-2605.1999.00196.x · Cited by 146 · see citing works
The use of treatments for erectile dysfunction among survivors of prostate carcinoma
Schover, L. R., Fouladi, R. T., Warneke, C. L., Neese, L., Klein, E. A., Zippe, C., & Kupelian, P. A. (2002) · Cancer · doi:10.1002/cncr.10970 · Cited by 127 · see citing works
Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation
Thompson, C. A., Shanafelt, T. D., & Loprinzi, C. L. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-474 · Cited by 84 · see citing works
Mulhall, J., Althof, S. E., Brock, G. B., Goldstein, I., Jünemann, K.-P., & Kirby, M. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00441.x · Cited by 84 · see citing works
How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment
Hatzimouratidis, K., & Hatzichristou, D. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0545-6 · Cited by 68 · see citing works
Evaluation and Management of Erectile Dysfunction
Burnett, A. L. (2012) · Campbell-Walsh Urology · doi:10.1016/b978-1-4160-6911-9.00024-4 · Cited by 28 · see citing works
Erectile dysfunction and its pharmacology: An overview
Patnaik, S. K., Polimati, H., & Pragada, R. R. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i2.15183 · Cited by 3 · see citing works
“Alprostadil used in intracavernous injection can be applied transurethrally at a higher dose (250-1000 μg) as a therapy for ED with a success rate of 40-69% [32-35].”
Background
- Authors
- Padma-Nathan, H., Hellstrom, W. J. G., Kaiser, F. E., Labasky, R. F., Lue, T. F., Nolten, W. E., Norwood, P. C., Peterson, C. A., Shabsigh, R., Tam, P. Y., Place, V. A., Gesundheit, N., Cowley, C., Nemo, K. J., Spivack, A. P., Stephens, D. E., & Todd, L. K.
- Affiliations
- University of Southern California (US)
- Tulane University (US)
- Saint Louis University (US)
- University of Utah (US)
- University of California, San Francisco (US)
- University of Wisconsin–Madison (US)
- Vivus (United States) (US)
- NewYork–Presbyterian Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-01-02
- Volume
- 336
- Issue
- 1
- Pages
- 1-7
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2312845168
- Cited by
- 574
- References
- 2
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 5 · 2023: 7 · 2022: 5 · 2021: 7 · 2020: 12 · 2019: 3 · 2018: 15 · 2017: 13 · 2016: 13 · 2015: 13 · 2014: 12 · 2013: 13 · 2012: 12
- FWCI
- 47.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Urology › Urological Disorders and Treatments
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Keywords
- erectile dysfunction, prostaglandin E1, home treatment, organic erectile dysfunction, penile pain, hypotension, sexual intercourse, vascular disease, diabetes mellitus
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alprostadil, Coitus, Double-Blind Method, Drug Administration Routes, Humans, Erectile Dysfunction, Male, Middle Aged, Prospective Studies, Urethra, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
